Advertisement

Intracerebroventricular Injection of Streptozotocin — An Animal Model for Sporadic Alzheimer’s Disease?

  • Dorothea Müller
  • Konstanze Plaschke
  • Siegfried Hoyer
Part of the Advances in Behavioral Biology book series (ABBI, volume 44)

Abstract

In normoglycemic patients with either incipient early-onset or incipient late-onset dementia of the Alzheimer type (DAT), the predominant disturbance consists of a significant reduction in cerebral glucose utilization. Cerebral blood flow and oxygen consumption is changed only in late-onset dementia types and is most severely decreased in advanced late-onset dementia (Hoyer et al.,1991). Reductions in resting state regional brain metabolism are roughly proportional to the severity of dementia. These reductions are greater in association than in primary sensory and motor neocortical regions and correlate with the distribution of neuropathology and cell loss after death (for review, see Rapoport, 1991).

Keywords

Phosphoglycerate Mutase Cerebral Glucose Utilization Glycolytic Enzyme Activity Normoglycemic Patient Diabetogenic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Backstrom, J.R., Miller, C.A., and Takes, Z.A., 1992, Characterization of neutral proteinases from Alzheimer-affected and control brain specimens: identification of calcium-dependent metalloproteinases from the hippocampus, J. Neurochem. 58: 983–992.PubMedCrossRefGoogle Scholar
  2. Baskin, D.G., Porte, D., Jr, Guest, K., and Dorsa, M., 1983, Regional concentration of insulin in the rat brain, Endocrinology 112: 898–903.PubMedCrossRefGoogle Scholar
  3. Benzi, G., Pastoris, O., Fenton, S., and Villa, R.F., 1987, Modifications in cerebral lipid metabolism by severe glucose deprivation during aging, Neurobiol. Aging 8: 457–463.PubMedCrossRefGoogle Scholar
  4. Brooksbank, B.W.L., and Martinez, M., 1989, Lipid abnormalities in the brain in adult Down’s syndrome and Alzheimer’s disease, Mol. Chem. Neuropathol. 11: 157–185.PubMedCrossRefGoogle Scholar
  5. Hoyer, S., and Nitsch, R., 1989, Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type, J. Neural Transm. 75: 227–232.PubMedCrossRefGoogle Scholar
  6. Hoyer, S., Nitsch, R., and Oesterreich, K., 1991, Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases, J. Neural Transm. (P-D Sect) 3: 1–14.Google Scholar
  7. Hoyer, S., Prem, L., Sorbi S., and Amaducci, L., 1993, Stimulation of glycolytic key enzymes in cerebral cortex by insulin, NeuroReport 4: 991–993.PubMedCrossRefGoogle Scholar
  8. Iwangoff, P., Armbruster, R., Enz, A., Meier-Ruge,W., and Sandoz, P., 1980, Glycolytic enzymes from human autoptic brain cortex: normally aged and demented cases, in: “Biochemistry of Dementia”, P.J. Roberts, ed., Wiley, Chichester.Google Scholar
  9. Junod, A., Lambert, A.E., Stauffacher, W., and Renold, A.E., 1968, Diabetogenic action of streptozotocin: relationship of dose to metabolic response, J. Clin. Invest. 48: 2129–2139.CrossRefGoogle Scholar
  10. Kadowaki, T., Kasuga, M., Akanuma, Y., Ezaki, O., and Takaku, F., 1984, Decreased autophosphorylation of the insulin receptor-kinase in streptozotocin diabetic rats, J. Biol. Chem. 259: 14208–14216.PubMedGoogle Scholar
  11. Liguri, G., Taddei, N., Nassi, P., Latorraca, S., Nediani, C., and Sorbi, S., 1990, Changes in Nat, K*–ATPase, Ca’ -ATPase and some soluble enzymes related to energy metabolism in brains of patients with Alzheimer’s disease, Neurosci. Lett. 112: 338–342.PubMedCrossRefGoogle Scholar
  12. Nitsch, R., and Hoyer, S., 1991, Local action of the diabetogenic drug, streptozotocin, on glucose and energy metabolism in rat brain cortex, Neurosci. Lett. 128: 199–202.PubMedCrossRefGoogle Scholar
  13. Nitsch, R.M., Blusztajn, J.K., Pittas, A.G., Slack, B.E., Growdon, J.H., and Wurtman, R.J., 1992, Evidence for a membrane defect in Alzheimer disease brain, Proc. Natl. Acad. Sci. USA 89: 1671–1675.PubMedCrossRefGoogle Scholar
  14. Padmini, S., and Rao, P.S., 1991, Enhanced ß-oxidative utilization of [1!`C] palmitate during active myelinogenesis in developing rat brain under nutritional stress, Lipids 26: 83–85.PubMedCrossRefGoogle Scholar
  15. Perry, E.K., Perry, R.H., Tomlinson, B.E., Blessed, G., and Gibson, P.H., 1980, Coenzyme A-acetylating enzymes in Alzheimer’s disease: possible cholinergic ‘compartment’ of pyruvate dehydrogenase, Neurosci. Lett. 18: 105–110.PubMedCrossRefGoogle Scholar
  16. Plaschke, K., and Hoyer, S., 1993, Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus, Int. J. Dev. Neurosci. 11: 477–483PubMedCrossRefGoogle Scholar
  17. Rapoport, S.I., 1991, Positron emission tomography in Alzheimer’s disease in relation to disease pathogenesis: a critical review, Cerebrovasc. Brain Metab. Rev. 3: 297–335.PubMedGoogle Scholar
  18. Saito, K.-I., Elce, J.S., Hamos, J.E., and Nixon, R.A., 1993, Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease, a potential molecular basis for neuronal degeneration, Proc. Natl. Acad. Sci. USA 90: 2628–2632.PubMedCrossRefGoogle Scholar
  19. Siesj6, B.K., 1978, “Brain Energy Metabolism”, Wiley, Chichester.Google Scholar
  20. Unger, J.W., Livingston, J.N., and Moss, A.M., 1991, Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects, Prog. Neurobiol. 36: 343–362.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Dorothea Müller
    • 1
  • Konstanze Plaschke
    • 1
  • Siegfried Hoyer
    • 1
  1. 1.Department of Pathochemistry and General NeurochemistryUniversity of HeidelbergHeidelbergGermany

Personalised recommendations